tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Hutchmed’s Phase I Study on HMPL-306: A Potential Game-Changer for Glioma Treatment
PremiumCompany AnnouncementsHutchmed’s Phase I Study on HMPL-306: A Potential Game-Changer for Glioma Treatment
28d ago
Hutchmed’s Phase I Study on HMPL-306: Market Implications and Study Insights
Premium
Company Announcements
Hutchmed’s Phase I Study on HMPL-306: Market Implications and Study Insights
29d ago
Hutchmed price target raised to $28 from $27 at BofA
Premium
The Fly
Hutchmed price target raised to $28 from $27 at BofA
1M ago
HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
PremiumRatingsHUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
5M ago
Hutchmed Reports Strong 2024 Growth and Profitability
Premium
Company Announcements
Hutchmed Reports Strong 2024 Growth and Profitability
5M ago
Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
Premium
The Fly
Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
5M ago
Hutchmed price target raised to $27 from $26 at BofA
PremiumThe FlyHutchmed price target raised to $27 from $26 at BofA
7M ago
Hutchmed announces NMPA approval for Orpathys supplemental new drug application
Premium
The Fly
Hutchmed announces NMPA approval for Orpathys supplemental new drug application
8M ago
Hutchmed price target lowered to $26 from $30 at BofA
Premium
The Fly
Hutchmed price target lowered to $26 from $30 at BofA
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100